Keywords: b-m, squibb/merck, co, pargluva, good, phi/ii, drug

B-M Squibb/Merck & Co's Pargluva: good PhI/II

Article | 20 June 2005

Print This

US drug majors Bristol-Myers Squibb and Merck & Co say that results from a Phase III active-controlled study and a long-term ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in